Lobbying registration dated 2026-02-27
Registrant: David Goodman
Client: Pharmascience Inc.
Targeted institutions:
Transport Canada (TC)
Finance Canada (FIN)
Public Services and Procurement Canada (PSPC)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Global Affairs Canada (GAC)
Health Canada (HC)
Government funding received:
Institution: Canada Economic Development for Quebec Regions
Amount: 901000.00
Institution: Innovation, Science and Economic Development Canada (ISED)
Amount: 9561036.00
Institution: Investissement Québec
Amount: 8126058.00
Lobbying activity details:
Policies aimed at facilitating generic drug repurposing.
Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
Discussion regarding the launch of new branded product in the rare disease space
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
Policies aimed at reinforcing pharmaceutical supply chain.
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.